A Robotic System with EMG-Triggered Functional Eletrical Stimulation for Restoring Arm Functions in Stroke Survivors.


Journal

Neurorehabilitation and neural repair
ISSN: 1552-6844
Titre abrégé: Neurorehabil Neural Repair
Pays: United States
ID NLM: 100892086

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 4 3 2021
medline: 16 11 2021
entrez: 3 3 2021
Statut: ppublish

Résumé

Robotic systems combined with Functional Electrical Stimulation (FES) showed promising results on upper-limb motor recovery after stroke, but adequately-sized randomized controlled trials (RCTs) are still missing. To evaluate whether arm training supported by RETRAINER, a passive exoskeleton integrated with electromyograph-triggered functional electrical stimulation, is superior to advanced conventional therapy (ACT) of equal intensity in the recovery of arm functions, dexterity, strength, activities of daily living, and quality of life after stroke. A single-blind RCT recruiting 72 patients was conducted. Patients, randomly allocated to 2 groups, were trained for 9 weeks, 3 times per week: the experimental group performed task-oriented exercises assisted by RETRAINER for 30 minutes plus ACT (60 minutes), whereas the control group performed only ACT (90 minutes). Patients were assessed before, soon after, and 1 month after the end of the intervention. Outcome measures were as follows: Action Research Arm Test (ARAT), Motricity Index, Motor Activity Log, Box and Blocks Test (BBT), Stroke Specific Quality of Life Scale (SSQoL), and Muscle Research Council. All outcomes but SSQoL significantly improved over time in both groups ( Hybrid robotic systems, allowing to perform personalized, intensive, and task-oriented training, with an enriched sensory feedback, was superior to ACT in improving arm functions and dexterity after stroke.

Sections du résumé

BACKGROUND
Robotic systems combined with Functional Electrical Stimulation (FES) showed promising results on upper-limb motor recovery after stroke, but adequately-sized randomized controlled trials (RCTs) are still missing.
OBJECTIVE
To evaluate whether arm training supported by RETRAINER, a passive exoskeleton integrated with electromyograph-triggered functional electrical stimulation, is superior to advanced conventional therapy (ACT) of equal intensity in the recovery of arm functions, dexterity, strength, activities of daily living, and quality of life after stroke.
METHODS
A single-blind RCT recruiting 72 patients was conducted. Patients, randomly allocated to 2 groups, were trained for 9 weeks, 3 times per week: the experimental group performed task-oriented exercises assisted by RETRAINER for 30 minutes plus ACT (60 minutes), whereas the control group performed only ACT (90 minutes). Patients were assessed before, soon after, and 1 month after the end of the intervention. Outcome measures were as follows: Action Research Arm Test (ARAT), Motricity Index, Motor Activity Log, Box and Blocks Test (BBT), Stroke Specific Quality of Life Scale (SSQoL), and Muscle Research Council.
RESULTS
All outcomes but SSQoL significantly improved over time in both groups (
CONCLUSIONS
Hybrid robotic systems, allowing to perform personalized, intensive, and task-oriented training, with an enriched sensory feedback, was superior to ACT in improving arm functions and dexterity after stroke.

Identifiants

pubmed: 33655789
doi: 10.1177/1545968321997769
doi:

Banques de données

ClinicalTrials.gov
['NCT03171649']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

334-345

Auteurs

Emilia Ambrosini (E)

Politecnico di Milano, Milan, Italy.

Giulio Gasperini (G)

Villa Beretta Rehabilitation Center, Costamasnaga, Italy.

Johannes Zajc (J)

Ottobock Health Products GmbH, Vienna, Austria.

Nancy Immick (N)

Asklepios Neurologische Klinik Falkenstein, Königstein, Germany.

Andreas Augsten (A)

Asklepios Neurologische Klinik Falkenstein, Königstein, Germany.

Mauro Rossini (M)

Villa Beretta Rehabilitation Center, Costamasnaga, Italy.

Roberto Ballarati (R)

Villa Beretta Rehabilitation Center, Costamasnaga, Italy.

Micheal Russold (M)

Ottobock Health Products GmbH, Vienna, Austria.

Simona Ferrante (S)

Politecnico di Milano, Milan, Italy.

Giancarlo Ferrigno (G)

Politecnico di Milano, Milan, Italy.

Thomas Schauer (T)

Technische Universität Berlin, Germany.

Constantin Wiesener (C)

Technische Universität Berlin, Germany.

Margit Gfoehler (M)

Technische Universität Wien, Vienna, Austria.

Markus Puchinger (M)

Technische Universität Wien, Vienna, Austria.

Mathias Weber (M)

Hasomed GmbH, Magdeburg, Germany.

Sebastian Weber (S)

Hasomed GmbH, Magdeburg, Germany.

Alessandra Pedrocchi (A)

Politecnico di Milano, Milan, Italy.

Franco Molteni (F)

Villa Beretta Rehabilitation Center, Costamasnaga, Italy.

Karsten Krakow (K)

Asklepios Neurologische Klinik Falkenstein, Königstein, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH